Adaptive Biotechnologies Corp (NASDAQ: ADPT) closed the day trading at $3.78 down -5.26% from the previous closing price of $3.99. In other words, the price has decreased by -$0.2100 from its previous closing price. On the day, 3411459 shares were traded. ADPT stock price reached its highest trading level at $3.8000 during the session, while it also had its lowest trading level at $3.4000.
Ratios:
For a better understanding of ADPT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.71.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $15.
Piper Sandler Upgraded its Neutral to Overweight on December 21, 2022, whereas the target price for the stock was revised from $7.50 to $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 16 when PISKEL KYLE sold 259 shares for $4.13 per share. The transaction valued at 1,070 led to the insider holds 87,305 shares of the business.
SOOD NITIN sold 10,550 shares of ADPT for $68,997 on Aug 08. The Chief Commercial Officer, MRD now owns 214,808 shares after completing the transaction at $6.54 per share. On Aug 07, another insider, SOOD NITIN, who serves as the Chief Commercial Officer, MRD of the company, sold 5,652 shares for $6.78 each. As a result, the insider received 38,321 and left with 225,358 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 547.24M and an Enterprise Value of 299.61M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.22 while its Price-to-Book (P/B) ratio in mrq is 1.78. Its current Enterprise Value per Revenue stands at 1.76 whereas that against EBITDA is -1.58.
Stock Price History:
Over the past 52 weeks, ADPT has reached a high of $9.08, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is 4.2172, while the 200-Day Moving Average is calculated to be 5.5226.
Shares Statistics:
Over the past 3-months, ADPT traded about 1.43M shares per day on average, while over the past 10 days, ADPT traded about 1.15M shares per day. A total of 145.08M shares are outstanding, with a floating share count of 141.80M. Insiders hold about 2.27% of the company’s shares, while institutions hold 95.40% stake in the company. Shares short for ADPT as of Feb 15, 2024 were 9.19M with a Short Ratio of 6.41, compared to 8.76M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.35% and a Short% of Float of 8.15%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$0.37, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.31 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.29 and -$1.37 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$1.06, with 6 analysts recommending between -$0.65 and -$1.29.
Revenue Estimates
7 analysts predict $38.21M in revenue for the current quarter. It ranges from a high estimate of $40M to a low estimate of $34.8M. As of the current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $37.65M, an estimated increase of 1.50% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $183.4M, while the lowest revenue estimate was $170M, resulting in an average revenue estimate of $175.61M. In the same quarter a year ago, actual revenue was $170.28M, up 3.10% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $220.99M in the next fiscal year. The high estimate is $256.8M and the low estimate is $195.5M. The average revenue growth estimate for next year is up 25.80% from the average revenue estimate for this year.
